BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garrido F. MHC/HLA Class I Loss in Cancer Cells. Adv Exp Med Biol 2019;1151:15-78. [PMID: 31140106 DOI: 10.1007/978-3-030-17864-2_2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Nie D, Fang Q, Li B, Cheng J, Li C, Gui S, Zhang Y, Zhao P. Research advances on the immune research and prospect of immunotherapy in pituitary adenomas. World J Surg Oncol 2021;19:162. [PMID: 34090476 DOI: 10.1186/s12957-021-02272-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhu X, Li S, Xu B, Luo H. Cancer evolution: A means by which tumors evade treatment. Biomed Pharmacother 2021;133:111016. [PMID: 33246226 DOI: 10.1016/j.biopha.2020.111016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
3 Mariotti FR, Quatrini L, Munari E, Vacca P, Tumino N, Pietra G, Mingari MC, Moretta L. Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. Br J Pharmacol 2020;177:2889-903. [PMID: 32335915 DOI: 10.1111/bph.15081] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Torres-Pineda DB, Mora-García ML, García-Rocha R, Hernández-Montes J, Weiss-Steider B, Montesinos-Montesinos JJ, Don-López CA, Marín-Aquino LA, Muñóz-Godínez R, Ibarra LRÁ, López Romero R, Monroy-García A. Adenosine augments the production of IL-10 in cervical cancer cells through interaction with the A2B adenosine receptor, resulting in protection against the activity of cytotoxic T cells. Cytokine 2020;130:155082. [PMID: 32259773 DOI: 10.1016/j.cyto.2020.155082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Brentville VA, Metheringham RL, Daniels I, Atabani S, Symonds P, Cook KW, Vankemmelbeke M, Choudhury R, Vaghela P, Gijon M, Meiners G, Krebber WJ, Melief CJM, Durrant LG. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses. J Immunother Cancer 2020;8:e000560. [PMID: 32561639 DOI: 10.1136/jitc-2020-000560] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
6 Quintana Á, Peg V, Prat A, Moliné T, Villacampa G, Paré L, Galván P, Dientsmann R, Schmid P, Curigliano G, Muñoz-Couselo E, Perez-García J, Marti M, Blanco-Heredia J, Anjos CD, Vazquez M, De Mattos-Arruda L, Cortés J. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. Eur J Cancer 2021;148:134-45. [PMID: 33743482 DOI: 10.1016/j.ejca.2021.01.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fangazio M, Ladewig E, Gomez K, Garcia-Ibanez L, Kumar R, Teruya-Feldstein J, Rossi D, Filip I, Pan-Hammarström Q, Inghirami G, Boldorini R, Ott G, Staiger AM, Chapuy B, Gaidano G, Bhagat G, Basso K, Rabadan R, Pasqualucci L, Dalla-Favera R. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2021;118:e2104504118. [PMID: 34050029 DOI: 10.1073/pnas.2104504118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Cózar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E. Tumor-Infiltrating Natural Killer Cells. Cancer Discov 2021;11:34-44. [PMID: 33277307 DOI: 10.1158/2159-8290.CD-20-0655] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
9 Paston SJ, Brentville VA, Symonds P, Durrant LG. Cancer Vaccines, Adjuvants, and Delivery Systems. Front Immunol 2021;12:627932. [PMID: 33859638 DOI: 10.3389/fimmu.2021.627932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Klein E, Hau AC, Oudin A, Golebiewska A, Niclou SP. Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy. Front Oncol 2020;10:604121. [PMID: 33364198 DOI: 10.3389/fonc.2020.604121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
11 Fisher K, Hazini A, Seymour LW. Tackling HLA Deficiencies Head on with Oncolytic Viruses. Cancers (Basel) 2021;13:719. [PMID: 33578735 DOI: 10.3390/cancers13040719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Tallima H, Azzazy HME, El Ridi R. Cell surface sphingomyelin: key role in cancer initiation, progression, and immune evasion. Lipids Health Dis 2021;20:150. [PMID: 34717628 DOI: 10.1186/s12944-021-01581-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhu Z, Gregg K, Zhou W. iRGvalid: A Robust in silico Method for Optimal Reference Gene Validation. Front Genet 2021;12:716653. [PMID: 34422018 DOI: 10.3389/fgene.2021.716653] [Reference Citation Analysis]
14 Dass SA, Selva Rajan R, Tye GJ, Balakrishnan V. The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy. Hum Vaccin Immunother 2021;17:2981-94. [PMID: 33989511 DOI: 10.1080/21645515.2021.1913960] [Reference Citation Analysis]
15 Sordo-Bahamonde C, Vitale M, Lorenzo-Herrero S, López-Soto A, Gonzalez S. Mechanisms of Resistance to NK Cell Immunotherapy. Cancers (Basel) 2020;12:E893. [PMID: 32272610 DOI: 10.3390/cancers12040893] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
16 Ma J, Zhang JK, Yang D, Ma XX. Identification of novel prognosis-related genes in the endometrial cancer immune microenvironment. Aging (Albany NY) 2020;12:22152-73. [PMID: 33159014 DOI: 10.18632/aging.104083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhang P, He B, Cai Q, Tu G, Peng X, Zhao Z, Peng W, Yu F, Wang M, Tao Y, Wang X. Decreased IL-6 and NK Cells in Early-Stage Lung Adenocarcinoma Presenting as Ground-Glass Opacity. Front Oncol 2021;11:705888. [PMID: 34568032 DOI: 10.3389/fonc.2021.705888] [Reference Citation Analysis]
18 Hazini A, Fisher K, Seymour L. Deregulation of HLA-I in cancer and its central importance for immunotherapy. J Immunother Cancer 2021;9:e002899. [PMID: 34353849 DOI: 10.1136/jitc-2021-002899] [Reference Citation Analysis]
19 Zitvogel L, Perreault C, Finn OJ, Kroemer G. Beneficial autoimmunity improves cancer prognosis. Nat Rev Clin Oncol 2021;18:591-602. [PMID: 33976418 DOI: 10.1038/s41571-021-00508-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Muntjewerff EM, Meesters LD, van den Bogaart G, Revelo NH. Reverse Signaling by MHC-I Molecules in Immune and Non-Immune Cell Types. Front Immunol 2020;11:605958. [PMID: 33384693 DOI: 10.3389/fimmu.2020.605958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Arndt MF, Koohestani DM, Chobrutskiy BI, Mihyu MM, Diaz M, Gozlan EC, Yeagley M, Zaman S, Roca AM, Blanck G. TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates. Hum Immunol 2020;81:692-6. [PMID: 32950267 DOI: 10.1016/j.humimm.2020.08.007] [Reference Citation Analysis]
22 Yu P, Zhu L, Cui K, Du Y, Zhang C, Ma W, Guo J. B4GALNT2 Gene Promotes Proliferation, and Invasiveness and Migration Abilities of Model Triple Negative Breast Cancer (TNBC) Cells by Interacting With HLA-B Protein. Front Oncol 2021;11:722828. [PMID: 34589428 DOI: 10.3389/fonc.2021.722828] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Zhang J, Späth SS, Weissman SM, Katz SG. An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions. Methods Mol Biol 2020;2097:139-71. [PMID: 31776925 DOI: 10.1007/978-1-0716-0203-4_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Stern PL, Dalianis T. Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors. Viruses 2021;13:1234. [PMID: 34202255 DOI: 10.3390/v13071234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Nielsen AY, Ormhøj M, Traynor S, Gjerstorff MF. Augmenting engineered T-cell strategies in solid cancers through epigenetic priming. Cancer Immunol Immunother 2020;69:2169-78. [PMID: 32648166 DOI: 10.1007/s00262-020-02661-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Sznarkowska A, Mikac S, Pilch M. MHC Class I Regulation: The Origin Perspective. Cancers (Basel) 2020;12:E1155. [PMID: 32375397 DOI: 10.3390/cancers12051155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Jiang P, Veenstra RN, Seitz A, Nolte IM, Hepkema BG, Visser L, van den Berg A, Diepstra A. Interaction between ERAP Alleles and HLA Class I Types Support a Role of Antigen Presentation in Hodgkin Lymphoma Development. Cancers (Basel) 2021;13:414. [PMID: 33499248 DOI: 10.3390/cancers13030414] [Reference Citation Analysis]
28 Caruntu A, Scheau C, Tampa M, Georgescu SR, Caruntu C, Tanase C. Complex Interaction Among Immune, Inflammatory, and Carcinogenic Mechanisms in the Head and Neck Squamous Cell Carcinoma. Adv Exp Med Biol 2021. [PMID: 33650087 DOI: 10.1007/5584_2021_626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]